XML 51 R32.htm IDEA: XBRL DOCUMENT v3.22.4

Revenues (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

						Year ended December 31, 2022																		Year ended December 31, 2021																		Year ended December 31, 2020
						U.S.						ROW						Total						U.S.						ROW						Total						U.S.						ROW						Total
ENBREL						$	4,044					$	73					$	4,117					$	4,352					$	113					$	4,465					$	4,855					$	141					$	4,996
Prolia						2,465						1,163						3,628						2,150						1,098						3,248						1,830						933						2,763
Otezla						1,886						402						2,288						1,804						445						2,249						1,790						405						2,195
XGEVA						1,480						534						2,014						1,434						584						2,018						1,405						494						1,899
Aranesp						521						900						1,421						537						943						1,480						629						939						1,568
Nplate						848						459						1,307						566						461						1,027						485						365						850
Repatha						608						688						1,296						557						560						1,117						459						428						887
KYPROLIS						850						397						1,247						736						372						1,108						710						355						1,065
Neulasta						959						167						1,126						1,514						220						1,734						2,001						292						2,293
EVENITY						533						254						787						331						199						530						191						159						350
Other products(1)						3,549						2,021						5,570						3,305						2,016						5,321						3,630						1,744						5,374
Total product sales(2)						17,743						7,058						24,801						17,286						7,011						24,297						17,985						6,255						24,240
Other revenues						852						670						1,522						908						774						1,682						511						673						1,184
Total revenues						$	18,595					$	7,728					$	26,323					$	18,194					$	7,785					$	25,979					$	18,496					$	6,928					$	25,424

____________

(1)    Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.

(2)    Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020.

Revenues earned from major customers

Certain information with respect to these customers was as follows (dollar amounts in millions):

			Years ended December 31,
			2022						2021						2020
McKesson Corporation:
Gross product sales			$	17,305					$	15,187					$	13,779
% of total gross revenues			35		%				33		%				32		%
AmerisourceBergen Corporation:
Gross product sales			$	15,443					$	14,783					$	14,743
% of total gross revenues			31		%				32		%				34		%
Cardinal Health, Inc.:
Gross product sales			$	8,319					$	7,681					$	7,332
% of total gross revenues			16		%				17		%				17		%

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration